[HTML][HTML] Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
M Maurer, W Berger, A Giménez-Arnau… - Journal of Allergy and …, 2022 - Elsevier
Background Chronic spontaneous urticaria (CSU) is inadequately controlled in many
patients and greatly affects quality of life. Remibrutinib, a highly selective, oral, novel
covalent Bruton tyrosine kinase inhibitor, might be effective in CSU. Objective This first-in-
patient trial aimed to evaluate the efficacy and safety of remibrutinib in CSU treatment and
characterize the dose–response. Methods This randomized, double-blind, placebo-
controlled, phase 2b dose-finding trial evaluated remibrutinib (12 weeks) in patients …
patients and greatly affects quality of life. Remibrutinib, a highly selective, oral, novel
covalent Bruton tyrosine kinase inhibitor, might be effective in CSU. Objective This first-in-
patient trial aimed to evaluate the efficacy and safety of remibrutinib in CSU treatment and
characterize the dose–response. Methods This randomized, double-blind, placebo-
controlled, phase 2b dose-finding trial evaluated remibrutinib (12 weeks) in patients …